Aclarion Hires Greg Gould as Chief Financial Officer

Aclarion Inc. has welcomed a new executive team member, appointing Greg Gould as chief financial officer (CFO), effective immediately. He succeeds long-time CFO John Lorbiecki, who has announced his plans to retire.

Gould has more than 30 years of public and private company experience and a track record of creating shareholder value, raising capital for growth, and collaborating with executive leadership to drive business profitability, revenue, and cash flow.

“We are thrilled to welcome Greg to our leadership team. His deep expertise in driving growth, capital strategies and financial leadership at publicly-traded companies will be invaluable as we execute on our vision of making Nociscan more widely available to physicians and patients with chronic low back pain,” Aclarion CEO Brent Ness said. “We thank John for his leadership and instrumental role in establishing the strong financial foundation for the company which has positioned us well for long-term success.”

Gould brings extensive financial and operational leadership experience to Aclarion. He has raised more than $450 million in public company debt and equity offerings, led 10-plus acquisitions, successfully sold three publicly-traded companies, and guided three organizations through uplistings to Nasdaq. He has built and streamlined accounting, finance, and administrative functions, with expertise spanning financial controllership, planning and analysis, compliance, consolidation, integration, and auditing. Most recently, Goould was CFO of Nanos Health, a pre-revenue pharmaceutical startup pioneering nanotechnology-based drug delivery solutions. He has also held CFO roles at seven publicly-traded companies, including Charlotte’s Web and Aytu BioScience, among others.

Gould earned a bachelor of science degree in business from the University of Colorado Boulder and is a certified public accountant (CPA).

“I’m excited to join Aclarion at such a pivotal time in its growth,” Gould stated. “The chance to build on the company’s recent momentum and help scale the business is incredibly compelling. Aclarion’s technology and vision to improve care for millions of patients suffering from chronic low back pain provides a powerful foundation for long-term value creation. I look forward to working closely with Brent and the entire Aclarion team, and leveraging my experience in capital markets, strategic transactions and operational excellence to help achieve this vision.”

Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s Nociscan solution is the first evidence-supported SaaS (software as a service) platform to non-invasively help physicians distinguish between painful and non-painful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain and has the potential to drive better surgical outcomes.

Aclarion leverages magnetic resonance spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to non-invasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies.